In a recent development, Jefferies analyst Kelly Shi has initiated coverage on Insmed (INSM, Financial) with a "Buy" rating. The coverage comes with a price target of $105.00 USD, reflecting Jefferies' optimistic outlook on INSM's potential market performance.
The announcement was made on May 13, 2025, indicating Jefferies' positive stance on the company's prospective growth. This new coverage by Jefferies does not reference any prior rating or price target, marking it as a fresh perspective on INSM's potential in the stock market.
This initiation by a notable analyst from Jefferies underscores the confidence in Insmed's (INSM, Financial) future, especially with the set price target of $105.00 USD. Investors and stakeholders may find this a crucial point of consideration given Jefferies' influence and reputation in financial circles.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Insmed Inc (INSM, Financial) is $97.71 with a high estimate of $109.00 and a low estimate of $89.00. The average target implies an upside of 44.22% from the current price of $67.75. More detailed estimate data can be found on the Insmed Inc (INSM) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Insmed Inc's (INSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Insmed Inc (INSM, Financial) in one year is $47.33, suggesting a downside of 30.14% from the current price of $67.75. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Insmed Inc (INSM) Summary page.
